Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
Sarang K Yoon, Kurt T. Hegmann, Matthew S. Thiese, J. Burgess, Katherine Ellingson, Karen Lutrick, Lauren E.W. Olsho, Laura Edwards, Brian Sokol, Alberto J. Caban‐Martinez, Natasha Schaefer Solle, John M. Jones, Harmony L. Tyner, Angela Hunt, Karley Respet, Manjusha Gaglani, Kayan Dunnigan, Spencer Rose, Allison L. Naleway, Holly C. Groom, Jennifer L. Kuntz, Ashley Fowlkes, Mark G. Thompson, Young M. Yoo
Abstract
Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers To the Editor: Data are needed regarding the effectiveness of a third dose of a messenger RNA (mRNA) vaccine against the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are based on scientifically rigorous, population-level surveillance. Health care personnel, first responders, and other essential and frontline workers who are being evaluated in the HEROES-RECOVER cohorts at eight sites in six states across the United States underwent weekly reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing regardless of the presence or absence of coronavirus disease 2019 (Covid-19) symptoms. 1-3 Here, we report the vaccine effectiveness of two or three doses of an mRNA vaccine against infection caused by the omicron and B.1.617.2 (delta) variants.